IRIS
FABRAZZO, Michele
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 11.115
NA - Nord America 5.381
AS - Asia 3.583
SA - Sud America 587
AF - Africa 42
Continente sconosciuto - Info sul continente non disponibili 4
OC - Oceania 3
Totale 20.715
Salva come PNG Salva come JPEG
Nazione #
RU - Federazione Russa 5.978
US - Stati Uniti d'America 5.327
IT - Italia 1.677
SG - Singapore 1.445
IE - Irlanda 1.097
CN - Cina 728
UA - Ucraina 593
HK - Hong Kong 573
BR - Brasile 518
GB - Regno Unito 475
VN - Vietnam 317
FR - Francia 294
DE - Germania 293
SE - Svezia 281
FI - Finlandia 150
TR - Turchia 127
JP - Giappone 100
GR - Grecia 98
IN - India 95
KR - Corea 76
NL - Olanda 44
PL - Polonia 35
CA - Canada 30
BD - Bangladesh 25
BE - Belgio 21
AR - Argentina 20
CH - Svizzera 16
ID - Indonesia 15
AT - Austria 14
IQ - Iraq 14
ZA - Sudafrica 14
CO - Colombia 12
ES - Italia 11
MX - Messico 11
EC - Ecuador 10
PY - Paraguay 9
VE - Venezuela 9
AE - Emirati Arabi Uniti 7
IR - Iran 7
MA - Marocco 7
UZ - Uzbekistan 7
EG - Egitto 6
PK - Pakistan 6
CZ - Repubblica Ceca 5
KE - Kenya 5
LB - Libano 5
LT - Lituania 5
MY - Malesia 5
PH - Filippine 5
PT - Portogallo 5
RO - Romania 5
TT - Trinidad e Tobago 5
CL - Cile 4
DZ - Algeria 4
EU - Europa 4
RS - Serbia 4
HU - Ungheria 3
IL - Israele 3
JM - Giamaica 3
JO - Giordania 3
OM - Oman 3
PE - Perù 3
SA - Arabia Saudita 3
TN - Tunisia 3
TW - Taiwan 3
AL - Albania 2
AU - Australia 2
AZ - Azerbaigian 2
BH - Bahrain 2
KZ - Kazakistan 2
NO - Norvegia 2
NP - Nepal 2
SV - El Salvador 2
BA - Bosnia-Erzegovina 1
BN - Brunei Darussalam 1
BO - Bolivia 1
BW - Botswana 1
ET - Etiopia 1
HN - Honduras 1
IS - Islanda 1
KG - Kirghizistan 1
LV - Lettonia 1
MD - Moldavia 1
MK - Macedonia 1
MR - Mauritania 1
NI - Nicaragua 1
NZ - Nuova Zelanda 1
PA - Panama 1
PS - Palestinian Territory 1
SI - Slovenia 1
SK - Slovacchia (Repubblica Slovacca) 1
UY - Uruguay 1
Totale 20.715
Salva come PNG Salva come JPEG
Città #
Moscow 2.211
Dublin 1.078
Jacksonville 881
Santa Clara 708
Hong Kong 569
Singapore 563
Chandler 542
San Jose 533
Ashburn 282
Princeton 172
Roxbury 136
Beijing 134
Ho Chi Minh City 120
Rome 104
Ann Arbor 96
Medford 91
Cambridge 89
Woodbridge 89
Milan 86
Boardman 84
Naples 78
The Dalles 77
Caserta 73
Seoul 71
New York 70
Wilmington 69
Bremen 68
Hanoi 65
Dallas 54
Hefei 54
Bengaluru 51
San Mateo 49
Nanjing 44
São Paulo 41
Aversa 37
Des Moines 37
Munich 34
Seattle 34
Düsseldorf 27
Los Angeles 25
Da Nang 23
Florence 21
Norwalk 20
Brussels 19
Catania 19
Jinan 18
Mountain View 18
Tokyo 18
Houston 17
Marigliano 17
Padova 17
Napoli 16
Bari 15
Bologna 15
Palermo 15
Nuremberg 14
Atlanta 13
Frankfurt am Main 13
Perugia 13
Radomsko 13
Shenyang 13
Torino 13
Warsaw 13
Fisciano 12
Haiphong 12
Rio de Janeiro 12
Chennai 11
Hangzhou 11
Brasília 10
Brooklyn 10
Curitiba 10
Helsinki 10
Memphis 10
Porto Alegre 10
Tianjin 10
Auburn Hills 9
Montreal 9
Nanchang 9
Salerno 9
Turin 9
Belo Horizonte 8
Cagliari 8
Chicago 8
Como 8
Genoa 8
Genova 8
Orem 8
Vienna 8
Viterbo 8
Catanzaro 7
Council Bluffs 7
Ferrara 7
Guangzhou 7
Istanbul 7
Kunming 7
London 7
Manaus 7
Parma 7
Pune 7
San Francisco 7
Totale 10.321
Salva come PNG Salva come JPEG
Nome #
SINDROME METABOLICA E TRATTAMENTO CON ANTIPSICOTICI: DIFFERENZE IN PAZIENTI CON DIAGNOSI DI SCHIZOFRENIA E DISTURBO BIPOLARE 637
Discrasie ematiche transitorie e persistenti indotte dalla clozapina durante le prime diciotto settimane di trattamento 510
CLOZAPINA E ALTRI ANTIPSICOTICI ATIPICI E TIPICI: INCIDENZA E DECORSO DELLE DISCRASIE EMATICHE DURANTE LE PRIME DICIOTTO SETTIMANE DI TRATTAMENTO 268
Trattamento combinato con clorimipramina ed aripiprazolo nella depressione resistente 223
TRATTAMENTO CON ANTIPSICOTICI E COMPARSA DI SINDROME METABOLICA: UNO STUDIO RETROSPETTIVO IN PAZIENTI SCHIZOFRENICI E BIPOLARI 189
Campania Region (Italy) spontaneous reporting system and preventability assessment through a case-by-case approach: a pilot study on psychotropic drugs 187
A systematic review on shared biological mechanisms of depression and anxiety in comorbidity with psoriasis, atopic dermatitis, and hidradenitis suppurativa 185
Central and peripheral peptides regulating eating behaviour and energy homeostasis in anorexia nervosa and bulimia nervosa: a literature review 177
Brain natriuretic peptide as a biomarker of asymptomatic clozapine-related heart dysfunction: a criterion for a more cautious administration. 174
Duration of Untreated Illness in Patients with Obsessive-Compulsive Disorder and Its Impact on Long-Term Outcome: A Systematic Review 169
Magnetic resonance imaging of a transient splenial lesion of the corpus callosum resolved within a week 164
Vitamin D Deficiency and Risk Factors Related to Acute Psychiatric Relapses in Patients with Severe Mental Disorders: A Preliminary Study 161
Cancro della mammella e Alessitimia: Freno o Incentivo alla prevenzione? 161
Bipolar Patients and Bullous Pemphigoid after Risperidone Long-Acting Injectable: A Case Report and a Review of the Literature 161
Antipsychotic treatment and metabolic syndrome: a retrospective study in schizophrenic and bipolar patients 158
Sindrome metabolica e utilizzo di antipsicotici in pazienti con diagnosi di schizofrenia e disturbo bipolare 157
Trattamento con antipsicotici e sindrome metabolica: uno studio retrospettivo in pazienti schizofrenici e bipolari 155
Antipsychotic treatment and metabolic syndrome: a retrospective study in schizophrenic and bipolar patients 153
A Multivariate Analysis of Depression Prevalence in Psoriasis Patients: A Cohort Study 152
L’Olanzapina è più rapida dell’Aloperidolo nell’indurre Sindrome Metabolica in pazienti schizofrenici ma non nei bipolari 149
Antipsychotic Treatment and Metabolic Syndrome: a Comparison between Schizophrenic and Bipolar Patients. 148
Aumento dei livelli plasmatici di colesterolo e trigliceridi nella bulimia nervosa 146
Transient and persistent blood dyscrasias induced by clozapine during the first 18 weeks of treatment 146
A hypothesis on Cotard’s syndrome as an evolution of obsessive-compulsive disorder 145
Serotonin transporter polymorphism and potential response to SSRIs in bulimia nervosa 143
Delirium and Psychiatric Sequelae Associated to SARS-CoV-2 in Asymptomatic Patients With Psychiatric History and Mild Cognitive Impairment as Risk Factors: Three Case Reports 142
Clozapine versus other antipsychotics during the first 18 weeks of treatment: A retrospective study on risk factor increase of blood dyscrasias 141
Second-Generation Antipsychotics' Effectiveness and Tolerability: A Review of Real-World Studies in Patients with Schizophrenia and Related Disorders 140
Circulating ghrelin is decreased in non-obese and obese women with binge eating disorder as well as in obese non-binge eating women, but not in patients with bulimia nervosa 140
Are antipsychotics useful in the treatment of anorexia nervosa? A review of the literature 140
Aripiprazole augmentation strategy in clomipramine-resistant depressive patients: An open preliminary study. 139
La depressione resistente al trattamento farmacologico: incremento dell’effetto antidepressivo della clorimipramina determinato dall’aripiprazolo 138
Investigating the Relationship between White Matter Connectivity and Motivational Circuits in Subjects with Deficit Schizophrenia: A Diffusion Tensor Imaging (DTI) Study 138
Blood levels of mianserin and amitriptyline and clinical response in aged depressed patients 136
Mismatch Negativity and P3a Impairment through Different Phases of Schizophrenia and Their Association with Real-Life Functioning 134
Brain-derived neurotrophic factor (BDNF) nello spettro del comportamento alimentare 133
Plasma levels of interleukin-6 and tumor necrosis factor alpha in chronic schizophrenia: effects of clozapine treatment 132
Molecular Psychiatry: regulation of gene function 132
From over- to under-weight: treatment of post-surgical anorexia nervosa in morbid obesity 131
Drug safety warnings in psychiatry: Adverse drug reactions' signaling from 2002 to 2014 131
Social Cognition Individualized Activities Lab for Social Cognition Training and Narrative Enhancement in Patients With Schizophrenia: A Randomized Controlled Study to Assess Efficacy and Generalization to Real-Life Functioning (Prot. n°: NCT05130853) 131
Bidirectional Relationship between HIV/HBV Infection and Comorbid Depression and/or Anxiety: A Systematic Review on Shared Biological Mechanisms 130
Correlati neurofisiologici della risposta clinica ai neurolettici tipici in pazienti schizofrenici al primo episodio di malattia 128
Risposta al trattamento con inibitori del reuptake della serotonina nel disturbo ossessivo-compulsivo ad esordio precoce 127
In rats the reserpine induced increase of brain NGF biosynthesis is mediated by corticosteroids 126
Factors Associated with Anxiety, Depression, and Quality of Life in Patients with Psoriasis: A Cross-Sectional Study 125
Altered ghrelin physiology in bulimia nervosa: integration with leptin changes 125
Metabolic Syndrome and Antipsychotic treatment: how about schizophrenia and bipolar disorder? 125
Pronounced, early increase in circulating leptin predicts lower weight gain during clozapine treatment 125
Changes of cholinergic, noradrenergic and serotonergic synaptic transmission indices elicited by Ethylcholine Aziridinium ion (AF64A) infused intraventricularly 124
Pemphigus and skin disease: A comparison of the incidence of stressful life events and personality disorders 123
Investigation of peptide YY and ghrelin responses to a test meal in bulimia nervosa. 122
Add-on oral olanzapine worsens hallucinations in schizoaffective disorder. 122
Discrasie ematiche transitorie e persistenti e trattamento con clozapina nelle prime diciotto settimane di terapia 121
Il trattamento farmacologico dei sintomi negativi della schizofrenia 119
Duration of untreated illness and outcome of the OCD: a three-year prospective study 119
Duration of untreated illness and outcome of obsessive-compulsive disorder: A naturalistic follow-up study. 119
At the Core of Depression: A Diagnostic Interview of the Core Features of Depression 118
Transsynaptic regulation of nerve growth factor gene expression 117
Comorbidity of obsessive-compulsive disorder and schizotypal personality disorder: Clinical response and treatment resistance to pharmacotherapy in a 3-year follow-up naturalistic study 117
Clozapine treatment and other atypical and typical antipsychotics: incidence and course of blood dyscrasias during the first eighteen weeks of treatment 115
Decreased blood levels of tumor necrosis factor-alpha in patients with obsessive-compulsive disorder 114
La sindrome metabolica e l’utilizzo di antipsicotici: quali differenze in schizofrenia e disturbo bipolare? 114
Studio longitudianle dei livelli plasmatici del cortisolo e delle catecolamine e della risposta al test al desametazone in pazienti con disordine affettivo bipolare 114
Plasma concentrations of amino acids in chronic schizophrenics treated with clozapine 113
Clinical and neurophysiological findings in schizophrenic patients with enlarged and normal ventricles 112
Long-term pharmacological treatment in schizophrenia 111
Leptin production in Bulimia Nervosa 111
Olanzapine Is Faster than Haloperidol in Inducing Metabolic Abnormalities in Schizophrenic and Bipolar Patients 111
Safety and Tolerability of Mood Stabilisers 110
Regulation of nerve growth factor receptor mRNA content by dexamethasone: in vitro and in vivo studies 109
L'anoressia mentale: aspetti eziopatogenetici clinici e terapeutici 109
L'ansia , la depressione e il movimento nell'anziano 109
Sciatic nerves transplanted into the CNS exhibit elevated nerve growth factor (NGF) protein levels 109
Peripheral brain derived neurotrophic factor (BDNF) in patients with unipolar depression or with bipolar I and II disorders 108
Livelli plasmatici degli aminoacidi nei pazienti affetti da schizofrenia cronica. 108
Pharmacology of Nerve Growth Factor biosynthesis in rat brain 108
La regolazione della sintesi del Nerve Growth factor nel Sistema Nervoso Centrale: gli steroidi come potenziali mediatori 108
Response to lithium prophylaxis in schizoaffective psychoses 107
Pronounced early increase in circulating leptin predicts a lower weight gain during clozapine treatment 107
Livelli plasmatici di TNF alfa in pazienti schizofrenici 107
Induction of Nerve Growth Factor gene expression by Beta-adrenergic receptor activation 107
Il monitoraggio plasmatico della clozapina e dei suoi principali metaboliti in pazienti schizofrenici 107
Effect of treatment duration on plasma levels of clozapine and n-desmethylclozapine in men and women 106
Sistemi di classificazione e nosografia dei disturbi psichiatrici 106
Plamsa leptin response to acute fasting and refeeding in untreated women with bulimia nervosa 105
Il monitoraggio plasmatico della clozapina e dei suoi principali metaboliti in pazienti schizofrenici 105
Opposite modifications in circulating leptin and solubile leptin receptor across the eating disorder spectrum 104
Transcriptional regulation of Nerve Growth Factor gene 104
Disturbo ossessivo-compulsivo ad esordio precoce: caratteristiche cliniche e risposta al trattamento 104
Regulation of Nerve Growth Factor receptor biosynthesis: in vitro and in vivo studies 104
Gli endocannabinoidi nei disturbi del comportamento alimentare: implicazioni fisiopatologiche 104
Long-term treatment with clozapine does not affect morning circulating levels of allopregnanolone and THDOC in patients with schizophrenia: a preliminary study 103
I neurosteroidi ed il recettore periferico delle benzodiazepine 103
Una strategia di trattamento combinato con cloripramina ed aripiprazolo nella depressione resistente 103
Circulating brain-derived neurotrophic factor is decreased in women with anorexia and bulimia nervosa but not in women with binge eating disorder: relationships to comorbid depression, psychopathology and hormonal variables 102
Steroid regulation of Nerve Growth Factor biosynthesis in the CNS 102
Use of clozapine in a patient with schizophrenia and polidipsia 101
Flattened cortisol awakening response in chronic patients with schizophrenia onset after cannabis exposure 100
Duration of untreated illness predicts 3-year outcome in patients with obsessive-compulsive disorder: A real-world, naturalistic, follow-up study 100
Totale 13.812
Salva come PNG Salva come JPEG
Categoria #
all - tutte 68.157
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 68.157
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202162 0 0 0 0 0 0 0 0 0 0 0 62
2021/20221.198 70 7 21 38 435 20 25 44 53 61 90 334
2022/20232.183 187 59 48 160 259 182 4 124 1.042 17 54 47
2023/2024991 80 27 81 76 287 58 35 60 14 26 84 163
2024/20252.766 22 36 49 76 428 394 230 203 413 555 206 154
2025/20269.668 328 315 387 440 812 5.600 495 293 419 287 178 114
Totale 20.882